Liminatus Pharma, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 29 Sep 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 18 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 24 Jul 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 27 May 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 26 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 25 Nov 2025 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Liminatus Pharma, Inc. — Overview & Financial Snapshot
Liminatus Pharma, Inc. (NasdaqCM: LIMN) is a Healthcare company, ranked #6,037 of 6,774 companies globally and #3,409 of 4,000 in United States on PositoAI, with a Positivity Score of 11,431. Its market capitalisation is ₹39.43 Cr ($4.18M), P/E ratio is -0.1 and P/B ratio is 13.90. It currently has 6 active red flags (PosiRed) and no yellow flags (PosiYellow) on record.
For financial statements, ratio trends and score history, Go Deep →